- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01564225
A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200
November 25, 2013 updated by: Edimer Pharmaceuticals
A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200, an Ectodysplasin-A1 Replacement Molecule, in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Adults
Following discussions with the FDA, a Phase 1 safety study is being initiated in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)-affected adults to develop safety and exposure data for EDI200 in anticipation of dosing XLHED-affected neonates.
Selecting XLHED-affected adults for this study provides a genetic match and biologic relevance to XLHED-affected neonates.
Both males and females will be enrolled, providing safety experience with EDI200 that will inform the planned neonate study as well as supportive data for potential future trials of antenatal EDI200 administration.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The Phase 1 study will enroll two cohorts of 3 XLHED-affected adults each, for a total of 6 subjects.
The size and scope of the study design are consistent with a drug development program in an ultra-rare disease and supported by the absence of safety concerns in a GLP non-human primate toxicology study.
All subjects must meet entry criteria including documentation of an EDA mutation.
Mirroring the conditions of use anticipated for the XLHED-affected newborn study, the adult cohort study incorporates a multiple-dose regimen associated with maximal efficacy in the newborn canine model.
Primary outcome measures will be safety, tolerability, immunogenicity and pharmacokinetics (PK).
While current data does not support a likelihood of clinical benefit for the XLHED-affected adult subjects, assays of pharmacodynamic/biologic activity are incorporated into the study design as exploratory objectives.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Ohio
-
Cincinnati, Ohio, United States, 45226
- Community Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females of child-bearing age, age 18-40 years
- Weight between 45 and 90 kg and a body mass index (BMI) from 18 to 29 kg/m2 (calculated using the following formula: weight in kilograms/(height in meters)2)
- Both males and females must be documented (via genetic testing) to carry an EDA mutation associated with XLHED; or have the clinical signs and symptoms associated with HED and/or a family history of HED and provide a blood sample to be sent for genetic testing that confirms an EDA mutation associated with XLHED
- No major medical issues that the investigator considers to be a contraindication of participation
- No scalp shaving in the month prior to first dose (males only)
- Women must use a "highly effective" method of contraception throughout the trial. Highly effective methods of birth control are defined as those, alone or in combination, which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. These methods include implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation or a vasectomized partner.
- No treatment with an investigational drug within the last three months
- Signed written informed consent
Exclusion Criteria:
- Women who are pregnant (confirmed via urine pregnancy test) or breastfeeding at screening or planning to become pregnant at any time during the study period
- Known history of hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
- Known history of HIV infection
- Known hypersensitivity to pilocarpine or pilocarpine-like muscarinic agonists
- Known hypersensitivity to lidocaine or lidocaine-like agents
- Presence of pacemakers
- Subjects who are not able or are not willing to comply with the procedures of this protocol
- Subject has a condition which in the opinion of the investigator would not allow for safe conduct of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EDI200
|
Cohort 1 will be dosed at 3 mg/kg/dose.
Cohort 2 will be dosed at 10 mg/kg/dose.
Both cohorts will receive 2 doses/week for a total of 5 doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: Up to 42 days
|
Up to 42 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory endpoint: change from baseline in biological activity
Time Frame: Baseline and 42 days
|
|
Baseline and 42 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ophir Klein, MD, PhD, University of California, San Francisco
- Principal Investigator: James Maynard, MD, Community Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
March 23, 2012
First Submitted That Met QC Criteria
March 26, 2012
First Posted (Estimate)
March 27, 2012
Study Record Updates
Last Update Posted (Estimate)
November 27, 2013
Last Update Submitted That Met QC Criteria
November 25, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ECP-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on X-linked Hypohidrotic Ectodermal Dysplasia
-
Edimer PharmaceuticalsActive, not recruitingX-linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
University Hospital ErlangenEdimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal DysplasiaGermany
-
Edimer PharmaceuticalsCompletedX Linked Hypohidrotic Ectodermal DysplasiaUnited States
-
EspeRare FoundationIqvia Pty Ltd; Pierre Fabre MedicamentRecruitingX-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)United States, Spain, France, Germany, Italy, United Kingdom
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal Dysplasia | Hypohidrotic Ectodermal DysplasiaUnited States
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal Dysplasia | Hypohidrotic Ectodermal DysplasiaSpain
-
Edimer PharmaceuticalsCompleted
-
Edimer PharmaceuticalsCompletedX-Linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
Edimer PharmaceuticalsCompletedX-Linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
Edimer PharmaceuticalsCompletedHypohidrotic Ectodermal Dysplasia | X-Linked Hypohidrotic Ectodermal DysplasiaUnited States
Clinical Trials on EDI200
-
Edimer PharmaceuticalsActive, not recruitingX-linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
Edimer PharmaceuticalsCompletedX-Linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy